Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma
Paolo F. Caimi, Gabriela Pacheco Sánchez, Ashish Sharma, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
Patrick Hayden, Claire Roddie, Peter Bader, et al.
Annals of Oncology (2021) Vol. 33, Iss. 3, pp. 259-275
Open Access | Times Cited: 281
How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy
Michael D. Jain, Melody Smith, Nirali N. Shah
Blood (2023)
Open Access | Times Cited: 84
Current understanding and management of CAR T cell-associated toxicities
Jennifer N. Brudno, James N. Kochenderfer
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 501-521
Closed Access | Times Cited: 54
CAR T Cells and T-Cell Therapies for Cancer
Jennifer N. Brudno, Marcela V. Maus, Christian S. Hinrichs
JAMA (2024) Vol. 332, Iss. 22, pp. 1924-1924
Closed Access | Times Cited: 17
Cardiovascular toxicities of immune therapies for cancer – a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio‐Oncology
Carlo G. Tocchetti, Dimitrios Farmakis, Yvonne Koop, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 10, pp. 2055-2076
Closed Access | Times Cited: 16
Novel strategies to manage CAR-T cell toxicity
Arthur Mulvey, Lionel Trueb, George Coukos, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 4
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings
Steven P. Treon, Camille N. Kotton, Jae‐Hyun Park, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 2
Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
Samane Abbasi, Milad Asghari Totmaj, Masoumeh Abbasi, et al.
Cancer Medicine (2022) Vol. 12, Iss. 7, pp. 7844-7858
Open Access | Times Cited: 54
Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India
Hamenth Kumar Palani, Arun Kumar Arunachalam, Mohammed Yasar, et al.
Bone Marrow Transplantation (2022) Vol. 58, Iss. 2, pp. 160-167
Closed Access | Times Cited: 52
Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome
Tim Lakomy, Dilara Akhoundova, Henning Nilius, et al.
Biomolecules (2023) Vol. 13, Iss. 2, pp. 382-382
Open Access | Times Cited: 31
Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
Larry D. Anderson, Binod Dhakal, Tania Jain, et al.
Transplantation and Cellular Therapy (2023) Vol. 30, Iss. 1, pp. 17-37
Open Access | Times Cited: 25
Mechanisms and management of CAR T toxicity
Christopher Ferreri, Manisha Bhutani
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 14
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Andrew D Hughes, David T. Teachey, Caroline Diorio
Seminars in Immunopathology (2024) Vol. 46, Iss. 3-4
Open Access | Times Cited: 11
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy
Zandra E. Walton, Matthew J. Frigault, Marcela V. Maus
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 3, pp. 263-279
Closed Access | Times Cited: 9
Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy
Meng-Yin Lin, Eunwoo Nam, Ryan M. Shih, et al.
The Journal of Experimental Medicine (2024) Vol. 221, Iss. 6
Closed Access | Times Cited: 9
Anakinra utilization in refractory pediatric CAR T-cell associated toxicities
Caroline Diorio, Anant Vatsayan, Aimee C. Talleur, et al.
Blood Advances (2022) Vol. 6, Iss. 11, pp. 3398-3403
Open Access | Times Cited: 35
The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis
Maria Maddalena Marrapodi, Annamaria Mascolo, Gabriella di Mauro, et al.
Frontiers in Pediatrics (2022) Vol. 10
Open Access | Times Cited: 33
The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions
Yanping Li, Ming Yue, Ruoqiu Fu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 32
Toxicities following CAR-T therapy for hematological malignancies
Rafael Hernani, Ana Benzaquén, Carlos Solano
Cancer Treatment Reviews (2022) Vol. 111, pp. 102479-102479
Closed Access | Times Cited: 32
Acute Kidney Injury in Critically Ill Patients with Cancer
Shruti Gupta, Prakash Gudsoorkar, Kenar D. Jhaveri
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 9, pp. 1385-1398
Open Access | Times Cited: 29
Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management
Mariam Markouli, Fauzia Ullah, Serhan Ünlü, et al.
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6330-6352
Open Access | Times Cited: 22
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines
Guido Ghilardi, Luca Paruzzo, Jakub Svoboda, et al.
Blood Advances (2023) Vol. 8, Iss. 3, pp. 653-666
Open Access | Times Cited: 17
Toxicity of CAR T-Cell Therapy for Multiple Myeloma
Aimaz Afrough, Pearl Abraham, Laura Turer, et al.
Acta Haematologica (2024), pp. 1-15
Open Access | Times Cited: 7
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-cell Lymphoma
Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 11, pp. 1065-1079
Open Access | Times Cited: 7
ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights
Alaa M. Ali, John F. DiPersio
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top